nursing-immunology-2019-scientifictracks

22 / 22

Page 39
Notes:
Volume 3 Journal of Nursing Research and Practice Nursing & Immunology 2019
March 11-12, 2019
Neonatology, Pediatric Nursing and Nursing
Immunology March 11-12, 2019 London, UK
World Congress on
8th World Congress on
&
Precision i/o clinical trial: Leveraging technology to gain insight into treatment efficacy
Olga Kubassova
Image Analysis Group, UK
C ancer treatment is reaching a breakthrough due to the
advances in Immunotherapy. The fundamental technology
behind immunotherapy is to harness the body’s own immune
system to attack cancer cells. The original purpose of immune
cells is to identify and destroy dangerous cells. However, cancer
cells have developed the ability to hide from the immune system
and therefore uncontrolled cell proliferation occurs which
leads to tumour growth. In principle, immunotherapy makes
cancer cells visible to the immune system. Therapies address
both: they target the body’s immune cells to identify cancer
cells and enable them to destroy the dangerous cells. Therefore,
immunotherapies are also called targeted therapies.For the
first time in cancer treatment it is possible to address tumour
heterogeneity in a more specific way. Immunotherapy enables
us to study and manipulate the tumour microenvironment.
However, to evaluate, proof and leverage the potential of
immunotherapies, it is essential to find methods which can
show the changes in the tumour microenvironment non-invasively.This is where advanced medical imaging followed by computer-
based analysis becomes paramount. Advanced Magnetic Resonance Imaging (MRI) in combination with algorithms to calculate
quantitative imaging biomarkers offer the unique opportunity to provide sensitive and specific tumour measurements. Especially
in clinical research studies which aim not only to test the safety of a drug but also the efficacy in a certain patient population, the
sensitive assessment of the therapy induced tumour microenvironmental changes are crucial for bringing the drug to the market.
Biography
A mathematician with over 10 years expertise in actively managing innovation in life science companies, Olga Kubassova, PhD, is a healthcare innovator and
biotech investor with passion for improving people’s health. She has co-authored over 60 publications, books and book chapters, has become a scientific adviser
to the UK government and EU funding bodies. She is a founder and CEO of IAG, Image Analysis Group, the imaging clinical research organization working with
top bio-pharma companies to maximize their chances of brining novel therapeutic agents to the market. She is a four-time winner of national and international
"Entrepreneur of the Year" awards. Olga’s ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice
and research, while expanding IAG's footprint and partnerships.
Fig. 01
Olga Kubassova, J Nursing Research and Practice, Volume 3
DOI: 10.4172/2632-251X-C1-002